Drug therapy for Parkinson's disease
Drug therapy for Parkinson's disease
复制标题
DOI：
10.1055/s-2007-971177
复制
发表时间：
2007-04-01
影响因子：
2.7
通讯作者：
Hermanowicz, Neal
中科院分区：
文献类型：
--
作者：
Hermanowicz, Neal
帕金森病的医学治疗的基本概念很简单，仍然基于左旋多巴和多巴胺激动剂增强多巴胺能传递。美国神经病学学会最近发表的实践参数和运动障碍协会主持的一项循证审查为运动并发症以及与帕金森氏症相关的认知和精神问题提供了指导。随着可注射和透皮的多巴胺激动剂的到来，以及通过口腔粘膜吸收的单胺抑制剂的到来，药物的选择和给药途径也在增加。尽管概念上很简单，但帕金森氏症患者的实际护理往往很复杂，需要考虑未来潜在的并发症和个性化的用药方案，并将从令人不快到严重干扰的药物的不良影响降至最低。
The fundamental concepts of the medical treatment of Parkinson's disease are simple, and remain based on the enhancement of dopaminergic transmission by means of levodopa and dopamine agonists. Recently published practice parameters from the American Academy of Neurology and an evidence-based review under the auspices of the Movement Disorder Society provide guidance on motor complications and also cognitive and psychiatric issues associated with Parkinson's disease. The choices of medications are increasing as are the routes of administration, with the arrival of injectable and transdermal dopamine agonists and a monoamine inhibitor absorbed via the buccal mucosa. Although simple conceptually, the actual care of patients with Parkinson's disease is often complex, requiring consideration of potential future complications and individualized medication regimens, and minimizing the adverse effects of medications that range from unpleasant to seriously disturbing.